Ebola: Translational science considerations

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Chiappelli, Francesco ^a,b,g   Bakhordarian, Andre ^a,b   Thames, April D ^c   Du, Angela M ^a   Jan, Allison L ^a   Nahcivan, Melissa ^a   Nguyen, Mia T ^a   Sama, Nateli ^a   Manfrini, Ercolano ^d   Piva, Francesco ^e   Rocha, Rafael Malagoli ^f   Maida, Carl A ^a  

^a UCLA SCHOOL OF DENTISTRY   (United States)

^b Evidence Based Decision Practice Based Research Network   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Regional Hospital of Ancona   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f A C CAMARGO CANCER CENTER   (Brazil)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Cell mediated immune surveillance; Ebola virus disease; Epidemic; M1 M2 macrophages; Pandemic; Syndemic; Vaccine; Zaire Ebola virus; Zoonotic

Indexed keywords

EBOLA VACCINE; MICRORNA; MICRORNA 1 3P; MICRORNA 1 5P; MICRORNA 1246; MICRORNA 196B 5P; MICRORNA 2; MICRORNA 2 3P; MICRORNA 320A; MONOCLONAL ANTIBODY; SELENIUM; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; COTE D'IVOIRE; DEMOCRATIC REPUBLIC CONGO; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EPIDEMIC; GENOMICS; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFLAMMATION; MEDICAL ANTHROPOLOGY; MOLECULAR PATHOLOGY; NEUROLOGIC DISEASE; PANDEMIC; PATIENT CARE; PREVALENCE; PROTEOMICS; PUBLIC HEALTH SERVICE; REVIEW; SOCIAL SECURITY; SOCIOLOGY; SUDAN; TELEHEALTH; TELEMEDICINE; TRANSCRIPTOMICS; TRANSLATIONAL RESEARCH; UGANDA; UNITED STATES; VIRUS TRANSMISSION; ANIMAL; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; PATHOLOGY; PHYSIOLOGY; VIROLOGY;

ANIMALS; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; HUMANS; PANDEMICS; TELEMEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84924337182     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0362-3     Document Type: Review

References (214)

1. Background reports: World Health Organization (WHO). Fact Sheet. Ebola virus disease. Fact sheet N°103. Updated September 2014. Centers for Disease Control and Prevention (CDC): Interim Guidance for Environmental Infection Control in Hospitals for Ebola Virus. October 3, 2014
2. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, et al. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis. 2007;196S:S142-7.
3. WHO Ebola Response Team. Ebola Virus Disease in West Africa The First 9 Months of the Epidemic and Forward Projections. N Engl J Med. 2014 Epub: Sep 22. 2014
4. Suzuki Y, Gojobori T. The origin and evolution of Ebola and Marburg viruses. Mol Biol Evol. 1997;14(8):800-6.
5. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae: Classification, names of taxa and viruses, and virus abbreviations. Arch Virol. 2010;155(12):2083-103.
6. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006;12(5):206-15.
7. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol. 2014;95(Pt 8):1619-24.
8. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849-62.
9. Wamala J, Lukwago L, Malimbo M, Nguku P, Yoti Z, Musenero M, et al. Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007-2008. Emerging Infectious Disease. 2010;16(7):21-9.
10. Fisher-Hoch SP, Platt GS, Neild GH, Southee T, Baskerville A, Raymond RT, et al. Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis. 1985;152(5):887-94.
11. Weidmann M, Mühlberger E, Hufert FT. Rapid detection protocol for filoviruses. J Clin Virol. 2004;30(1):94-9.
12. Formenty P, Leroy EM, Epelboin A, Libama F, Lenzi M, Sudeck H, et al. Detection of Ebola virus in oral fluid specimens during outbreaks of Ebola virus hemorrhagic fever in the Republic of Congo. Clin Infect Dis. 2006;42(11):1521-6.
13. Garamszegi S, Yen JY, Honko AN, Geisbert JB, Rubins KH, Geisbert TW, et al. Transcriptional correlates of disease outcome in anticoagulant-treated non-human primates infected with ebolavirus. PLoS Negl Trop Dis. 2014;8(7):e3061. ePub: 2014 Jul.
14. Nakajima H, Watanabe N, Shibata F, Kitamura T, Ikeda Y, Handa M. N-terminal region of CCAAT/enhancer-binding protein epsilon is critical for cell cycle arrest, apoptosis, and functional maturation during myeloid differentiation. J Biol Chem. 2006;281(20):14494-502.
15. Pulina MO, Sokolov AV, Zakharova ET, Kostevich VA, Vasilyev VB. Effect of lactoferrin on consequences of acute experimental hemorrhagic anemia in rats. Bull Exp Biol Med. 2010;149(2):219-22.
16. Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol. 2010;84(13):6615-25.
17. Bihrer V, Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, et al. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 2001;106(9):1663-9.
18. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368(18):1685-94.
19. Mitka M. Experimental RNA, therapy shows promise against Ebola virus in monkey studies. JAMA. 2010;304(1):31.
20. Hunt CL, Lennemann NJ, Maury W. Filovirus entry: a novelty in the viral fusion world. Viruses. 2012;4(2):258-75.
21. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132-7.
22. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 2003;58(1):47-56.
23. Barkhordarian A, Hacker B, Chiappelli F. Dissemination of Evidence-Based Standards of Care. Bioinformation. 2011;7:315-9.
24. Barkhordarian A, Ramchandani MH, Dousti M, Kelly-Gleason L, Chiappelli F. Disseminating the Best Available Evidence: New Challenges in Public Reporting of Health Care. Bioinformation. 2012;8:293-5.
25. Chiappelli F, Barkhordarian A, Arora R, Phi L, Giroux A, Uyeda M, et al. Reliability of Quality Assessments in Research Synthesis: Securing the Highest Quality Bioinformation for HIT. Bioinformation. 2012;8:691-4.
26. Barkhordarian A, Pellionisz P, Dousti M, Lam V, Gleason L, Dousti M, et al. Assessment of risk of bias in translational science. J Transl Med. 2013;11:184-90.
27. Chiappelli F. Fundamentals of Evidence-based Health Care and Translational Science. Heidelberg: Springer-Verlag. 2014.
28. Tambo E, Ugwu EC, Ngogang JY. Need of surveillance response systems to combat Ebola outbreaks and other emerging infectious diseases in African countries. Infect Dis Poverty. 2014 3:29. EPub Aug 5.
29. Barrett R, Kuzawa CW, McDade T, Armelagos GJ. Emerging and re-emerging infectious diseases: The third epidemiologic transition. Annu Rev Anthropol. 1998;27:247-71.
30. Armelagos GJ, Brown PJ, Turner B. Evolutionary, Historical and political economic perspectives on health and disease. Soc Sci Med. 2005;61:755-65.
31. Muehlenbein MP. Human-wildlife contact and emerging infectious diseases. In: Brondízio ES, Moran EF, editors. Human-environment interactions: Current and future directions. Dordrecht: Springer. 2013. p. 79-94.
32. Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife-Threats to biodiversity and human health. Science. 2000;287:443-9.
33. Chapman CA, Gillespie TR, Goldberg TL. Primates and the ecology of their infectious diseases: How will anthropogenic change affect host-parasite interactions? Evolutionary Anthropology. 2005;14:134-44.
34. Nading AM. Humans, animals, and health: From ecology to entanglement. Environment and Society: Advances in Research. 2013;4:60-78.
35. Daszak P. Risky behavior in the Ebola zone. Anim Conserv. 2006;9:366-7.
36. Brown H, Kelly AH. Material proximities and hotspots: Toward an anthropology of viral hemorrhagic fevers. Med Anthropol Q. 2014;28(2):280-303.
37. Hewlett BS, Amola RP. Cultural contexts of Ebola in Northern Uganda. Emerg Infect Dis. 2013;9(10):1242-8.
38. Hewlett BS, Hewlett BL. Ebola, culture, and politics: The anthropology of an emerging disease. Thompson Wadsworth: Belmont, CA. 2008.
39. Hewlett BS, Alain Epelboin A, Hewlett BL, Formenty P. Medical anthropology and Ebola in Congo: Cultural models and humanistic care. Bull Soc Pathol Exot. 2005;98:230-6.
40. Hewlett BL, Hewlett BS. Providing care and facing death: Nursing during Ebola outbreaks in Central Africa. J Transcult Nurs. 2005;16(4):289-97.
41. Bausch DG, Feldmann H, Geisbert TW, Bray M, Sprecher AG, Boumandouki O, et al. Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient. J Infect Dis. 2007;196:S136-41.
42. Roddy P, Weatherill D, Jeffs B, Abaakouk Z, Dorion C, Rodriguez J, et al. The Médecins Sans Frontières intervention in the Marburg Hemorrhagic Fever epidemic, Uige, Angola 2005. II. Lessons learned in the community. J Infect Dis. 2007;207:162-7.
43. Kinsman J. A time of fear": local, national, and international responses to a large Ebola outbreak in Uganda. Glob Health. 2012;8(15):1-12.
44. Calain P, Fiore N, Poncin M, Hurst SA. Research ethics and international epidemic response: The case of Ebola and Marburg hemorrhagic fevers. Public Health Ethics. 2009;2(1):7-29.
45. Leach M, Barry S, Hewlettt BS. Haemorrhagic Fevers: Narratives, politics and pathways. In: Dry S, Leach M, editors. Epidemics: Science, governance and social justice. London: Earthscan. 2010. p. 43-69.
46. Leach M, Scoones I. The social and political lives of zoonotic disease models: Narratives, science and policy. Soc Sci Med. 2013;88:10-7.
47. Farmer P. Social inequalities and emerging infectious diseases. Emerg Infect Dis. 1996;2(4):259-69.
48. Brown PJ, Armelagos GR, Maes KC. Humans in a world of microbes: Anthropology of infectious disease. In: Singer M, Erickson PI, editors. A companion to medical anthropology. Malden, MA: Wiley-Blackwell. 2011. p. 253-70.
49. Janes CR, Corbett KK, Jones JH, Trostle J. Emerging infectious diseases: The role of social sciences. Lancet. 2012;380:1884-6.
50. Singer M, Clair S. Syndemics and public health: Reconceptualizing disease in bio-social context. Med Anthropol Q. 2003;17(4):423-41.
51. Rock M, Buntain BJ, Hatfield JM, Hallgrimsson B. Animal-human connections, "one health, and the syndemic approach to prevention. Soc Sci Med. 2009;68:991-5.
52. Lynteris C. The time of epidemics. Camb Anthropol. 2014;32(1):24-31.
53. Raeymakers T. Reshaping the state in its margins: The state, the market and the subaltern on a Central African frontier. Crit Anthropol. 2012;32(3):334-50.
54. Lakoff A. The generic biothreat, or, how we became unprepared. Cult Anthropol. 2008;23(3):399-428.
55. Charles L, Briggs CL. Communicating biosecurity. Medical Anthropol. 2011;30(1):6-29.
56. Caduff C. On the verge of death: visions of biological vulnerability. Annu Rev Anthropol. 2014;43(3):1-17.
57. Harper I, Parker M. The politics and anti-politics of infectious disease control. Med Anthropol. 2014;33(3):198-205.
58. Gonzalez JP, Pourrut X, Leroy E. Ebolavirus and other filoviruses. Current topics in microbiology and immunology. Curr Top Microbiol Immunol. 2007;315:363-87.
59. Choi JH, Croyle MA. Emerging targets and novel approaches to Ebola virus prophylaxis and treatment. BioDrugs. 2013;27(6):565-83.
60. Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus-infected patients. Viruses. 2012;4(9):1668-86.
61. Ansari A. Clinical features and pathobiology of Ebolavirus infection. J Autoimmun. 2014;S0896:8411.
62. Martinez O, Valmas C, Basler CF. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology. 2007;364:342-54.
63. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature Reviews. 2008;8:958-69.
64. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl TropDis. 2014;14:e837.
65. Mahanty S, Hutchinson K, Agarwal S, Mcrae M, Rollin PE, Pulendre B. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol. 2003;170(6):2797-801.
66. Nekludov M, Antovic J, Bredbacka S, Blombäck M. Coagulation abnormalities associated with severe isolated traumatic brain injury: cerebral arterio-venous differences in coagulation and inflammatory markers. J Neurotrauma. 2007;24(1):174-80.
67. Berg LJ, Finkelstein LD, Lucas JA, Schwartzberg PL. Tec family kinases in T lymphocyte development and function. Annu Rev Immunol. 2005;23:549-600.
68. Wilson CJ, Finch CE, Cohen H. Cytokines and cognition- The case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50:2041-56.
69. Sparkman NL, Buchanan JB, Heyen JR, Chen J, Beverly JL, Johnson RW. Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci. 2006;26:10709-16.
70. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci. 2007;8:221-32.
71. Erta M, Quintana A, Hidalgo J. Interleukin-6, a Major Cytokine in the Central Nervous System. Int J Biol Sci. 2012;8(9):1254-66.
72. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A. 2003;100:13632-7.
73. Donegan JJ, Girotti M, Weinberg MS, Morilak DA. A novel role for brain interleukin-6: Facilitation of cognitive flexibility in rate orbitofrontal cortex. The Journal of Neuroscience. 2014;34(3):953-62.
74. Whitney NP, Eidem TM, Peng H, Huang Y, Zheng JC. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. J Neurochem. 2009;108:1343-59.
75. Baune T, Wiede F, Braun A, Golledge J, Arolt V, Koerner L. Cognitive dysfunction in mice deficient for TNF- and its receptor. Am J Med Genet B Neuropsychiatr Genet. 2008;147(7):1056-64.
76. Beste C, Baune BT, Falkenstein M, Konrad C. Variations in the TNF-α gene (TNF-α -308G → A) affect attention and action selection mechanisms in a dissociated fashion. J Neurophysiol. 2010;104(5):2523-31.
77. Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des. 2008;14(32):3408-16.
78. Plata-Salamán CR. Cytokines and feeding. Int J Obes. 2001;25(s5):S48-52.
79. Yao Y, Tsira SE. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell Mol Life Sci. 2014;71(4):683-97.
80. Hussain R, Ansari A, Talat N, Hasan Z, Dawood G. CCL2/MCP-1 Genotype-Phenotype in latent tuberculosis infection. PLoS One. 2011;6(10):e25803.
81. Uguccioni M, D'Apuzzo M, Loetscher M, Dewald B, Baggiolini M. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol. 1995;25:64-8.
82. Conant K, Garzino-Demo A, Nath A, McArthur JC, Halliday W, Power C, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998;95(6):3117-21.
83. Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J Neurochem. 2003;85:1299-311.
84. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutan MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A. 2002;99:13795-800.
85. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831-5.
86. Lehmann MH, Masanetz S, Kramer S, Erfle V. HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner. J Cell Sci. 2006;119(21):4520-30.
87. Letendre SL, Zheng JC, Kaul M, Yiannoutsos CT, Ellis RJ, Taylor MJ, et al. HIV Neuroimaging Consortium. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63-9.
88. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, Venturelli E, et al. Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol. 2011;63(4):538-43.
89. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156-61.
90. Graeber MB. Changing face of microglia. Science. 2010;330:783-8.
91. Abbott JN, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53.
92. Alcendor DJ, Charest AM, Zhu WQ, Vigil HE, Knobel SM. Infection and upregulation of proinflammatory cytokines in human brain vascular pericytes by human cytomegalovirus. J Neuroinflammation. 2012;9:95.
93. Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and 'instruct' them with pattern-recognition and motility programs. Nat Immunol. 2013;14:41-51.
94. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, Petersen MA, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227.
95. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20:131-47.
96. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173-85.
97. Hermann DM, Elai A. The abluminal endothelial membrane in neurovascular remodeling in health and disease. Sci Signal. 2012;5(236):re4.
98. Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120:1368-79.
99. Pardridge M. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv. 2003;3:90-105.
100. Wahl-Jensen VM, Afanasieva TA, Seebach J, Stroher U, Feldmann H, Schnittler HJ. Effects of Ebola virus glycoproteins on endothelial cell activation. American Society for Microbiology. 2005;16:10042-450.
101. Mu H, Chai H, Lin PH, Yao Q, Chen C. Current update on HIV-associated vascular disease and endothelial dysfunction. World J Surg. 2007;31(4):632-43.
102. Toborek M, Lee Y, Flora G, Pu H. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol. 2005;25(1):181-99.
103. Minagar A, Alexander JS. Blood-brain barrier disruption in multiple sclerosis. Mult Scler. 2003;9:540-9.
104. Murphy FA. Pathology of Ebola virus infection. In: Pattyn SR, editor. Ebolavirus haemorrhagic fever. Amsterdam: Elsevier/North-Holland Biomedical Press. 1978. p. 43-60.
105. Whitley RJ, Gnann JW. Viral encephalitis. Lancet. 2002;359:507-14.
106. Kauder SE, Racaniello VR. Poliovirus tropism and attenuation are determined after internal ribosome entry. J Clin Invest. 2004;113(12):1743-53.
107. Takada A. Filovirus tropism: cellular molecules for viral entry. Front Microbiol. 2012;6(3):34.
108. Papadopoulos MC, Manley GT, Krishna S, Verkman AS. Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J. 2004;18:1291-3.
109. Kaufman DM. Lumbar puncture and imaging. In D. Kaufman. Clinical Neurology for Psychiatrists. Sauders New York. 2006
110. Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, et al. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002;33:200-9.
111. Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol. 2014;10(6):7819.
112. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses. 2011;3(9):163449.
113. Leung DW, Prins KC, Basler CF, Amarasinghe GK. Ebolavirus VP35 is a multifunctional virulence factor. Virulence. 2010;1:526-31.
114. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005;175(2):1184-91.
115. Zampieri CA, Sullivan NJ, Nabel GJ. Immunopathology of highly virulent pathogens: insights from Ebola virus. Nat Immunol. 2007;8(11):1159-64.
116. Rogers NM, Ferenbach DA, Isenberg JS, Thomson AW, Hughes J. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nature Reviews Nephrology. 2014. Epub 30 September
117. Assas BM, Miyan JA, Pennock JL. Cross-talk between neural and immune receptors provides a potential mechanism of homeostatic regulation in the gut mucosa. Mucosal Immunol. 2014;7:1283-9.
118. Tacchetti C, Favre A, Moresco L, Meszaros P, Luzzi P, Truini M, et al. HIV is trapped and masked in the cytoplasm of lymph node follicular dendritic cells. Am J Pathol. 1997;150(2):533-42.
119. Gill PS, Arora DR, Arora B, Gill M, Gautam V, Karan J, et al. Lymphadenopathy an important guiding tool for detecting hidden HIV-positive cases: a 6-year study. J Int Assoc Physicians AIDS Care (Chic). 2007;6(4):269-72.
120. Bradfute SB, Warfield KL, Bavari S. Functional CD8+ T cell responses in lethal Ebola virus infection. J Immunol. 2008;180(6):4058-66.
121. Bradfute SB, Swanson PE, Smith MA, Watanabe E, McDunn JE, Hotchkiss RS, et al. Mechanisms and consequences of ebolavirus-induced lymphocyte apoptosis. J Immunol. 2010;184(1):327-35.
122. Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett. 2014;8(4):1461-9.
123. Bour-Jordan H, Bluestone JA. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev. 2009;229(1):41-66.
124. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180-205.
125. Kow NY, Mak A. Costimulatory pathways: physiology and potential therapeutic manipulation in systemic lupus erythematosus. Clin Dev Immunol. 2013. 245928. ePub July.
126. Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MC, et al. Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol. 2000;60(4):463-7.
127. Bray M, Geisbert TW. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol. 2005;37:1560-6.
128. Military Health System, US. Ebola Fact Sheet for Families of Deploying Personnel Fact. Sheet 10/17/2014.
129. Pandjassarame K, Sakharkar MK, Flower DR, Sadler K, Chiappelli F, Segal DM, et al. Designing HIV Gp120 Peptide Vaccines: Rhetoric or Reality For NeuroAids. Chapter 9. In: Goodkin K, Shapshak P, Verma A, editors. The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment. Washington, DC: ASM Press. 2008.
130. Meltzer MI, Atkins CY, Santibanez S, Knust B, Petersen BW, Ervin ED, et al. Estimating the future number of cases in the ebola epidemic Liberia and Sierra Leone, 20142015. MMWR Surveill Summ. 2014;26(63):1114.
131. Nyamathi AM, Fahey JL, Sands H, Casillas AM. Ebola virus: immune mechanisms of protection and vaccine development. Biol Res Nurs. 2003;4(4):276-88.
132. Wilson JA, Bosio CM, Hart MK. Ebola virus: the search for vaccines and treatments. Cell Mol Life Sci. 2001;58(1213):1826-41.
133. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345(6202):1369-72.
134. Editorial. Ebola vaccine trials raise ethical issues. Science. 2014;346:289-90.
135. Gehring G, Rohrmann K, Atenchong N, Mittler E, Becker S, Dahlmann F, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother. 2014;69(8):2123-31.
136. McCarthy M. US signs contract with ZMapp maker to accelerate development of the Ebola drug. BMJ. 2014;349:g5488.
137. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514(7520):47-53.
138. Pettitt J, Zeitlin L, Kim Do H, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5(199):199ra113.
139. Jerne NK. Towards a network theory of the immune system. Ann Immunol. 1974;125C:373-89.
140. Jäger A, Kuchroo VK. Effector and Regulatory T-cell Subsets in Autoimmunity and Tissue Inflammation. Scand J Immunol. 2010;72:173-84.
141. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med. 2014;20:62-8.
142. Muranski P, Restifo NP. Essentials of TH17 commitment and plasticity. Blood. 2013;121(13):2402-14.
143. Qu N, Xu M, Mizoguchi I, Furusawa J, Kaneko K, Watanabe K, et al. Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases. Clin Dev Immunol. 2013. 968549. Epub July 13.
144. Tan C, Gery I. The unique features of Th9 cells and their products. Crit Rev Immunol. 2012;32(1):1-10.
145. Gupta M, Mahanty S, Ahmed R, Rollin PE. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro. Virology. 2001;284(1):20-5.
146. Leroy EM, Baize S, Volchkov VE, Fisher-Hoch SP, Georges-Courbot MC, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and in a complex and interactive model of care strong inflammatory response. Lancet. 2000;355(9222):2210-5.
147. Dzik JM. The ancestry and cumulative evolution of immune reactions. Acta Biochemica Polonica. 2010;57:443-66.
148. Cooper EL. Evolution of immune systems from self/not self to danger to artificial immune systems (AIS). Physics of Life Reviews. 2010;7:55-78.
149. Janeway CA. The immune system evolved to dis- criminate infectious nonself from noninfectious self. Immunol Today. 1992;13:11-6.
150. Beutler BA. TLRs and innate immunity. Blood. 2009;113:399-407.
151. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637-50.
152. Morris SM. Arginine metabolism: boundaries of our knowledge. J Nutr. 2007;137(1):602-9.
153. Morris SM. Recent advances in arginine metabolism: roles and regulation of the arginases. Brit Jour Pharmacol. 2009;157:922-30.
154. Hibbs JB, Vavrin Z, Taintor RR. L-arginine is required for expression of the activated macro- phage effector mechanism causing selective metabolic inhibition in target cells. J Immunol. 1987;138:550-65.
155. Hibbs JB, Taintor RR, Vavrin Z. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science. 1987;235:473-6.
156. Murray PJ, Wynn TA. Protective and Pathogenic Functions of Macrophage Subsets. Nat Rev Immunol. 2011;11:723-37.
157. Mills CD. M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol. 2012;32:463-88.
158. Marinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Reports. 2014. 6:13. Ecollection March
159. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-50.
160. Mills CD. Macrophage arginine metabolism to ornithine/urea or nitric oxide/citrulline: A life or death issue. Crit Rev Immunol. 2001;21:399-425.
161. Nathan CF, Hibbs JB. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 1991;3:65-70.
162. McCall TB, Boughton-Smith NK, Palmer RM, Whittle BJ, Moncada S. Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J. 1989;261:293-6.
163. Bermudez LE. Production of transforming growth factor-beta by Mycobacterium avium-infected human macrophages is associated with unresponsiveness to IFN-gamma. J Immunol. 1993;150:1838-45.
164. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria- induced macrophages. Science. 1993;260:547-9.
165. Williams-Ashman HG, Canellakis ZN. Polyamines in mammalia biology and medicine. Perspect Biol Med. 1979;22:421-53.
166. Macatonia SE, Hosken NA, Litton M, Vieira P, Hsieh CS, Culpepper JA, et al. Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol. 1995;154:5071-9.
167. Wu G, Morris SM. Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336:1-17.
168. Stuehr DJ, Marletta MA. Induction of nitrite/nitrate synthesis in murine macrophages by BCG infection, lymphokines, or interferon-gamma. J Immunol. 1987;139:518-25.
169. Ding A, Nathan CF, Graycar J, Derynck R, Stuehr DJ, Srimal S. Macrophage deactivating factor and transforming growth factors-beta 1 -beta 2 and -beta 3 inhibit induction of macrophage nitrogen oxide synthesis by IFN-gamma. J Immunol. 1990;145:940-4.
170. Rosenthal AS, Shevach EM. Function of macrophages in antigen recognition by guinea pig T lymphocytes. I. Requirement for histocompatible macrophages and lymphocytes. J Exp Med. 1973;138:194-212.
171. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 1988;141:2407-12.
172. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol. 1995;154:5320-30.
173. Alleva DG, Kaser SB, Beller DI. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand Black/White F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol. 1998;161:6878-84.
174. Li J, Hunter CA, Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol. 1999;162:974-9.
175. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta, rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-71.
176. Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW, et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987;84:6020-4.
177. Stevens RB, Sutherland DE, Ansite JD, Saxena M, Rossini TJ, Levay-Young BK, et al. Insulin down-regulates the inducible nitric oxide synthase pathway, nitric oxide as cause and effect of diabetes? J Immunol. 1997;159:5329-35.
178. Toossi Z, Hirsch CS, Hamilton BD, Knuth CK, Friedlander MA, Rich EA. Decreased production of TGF-beta 1 by human alveolar macrophages compared with blood monocytes. J Immunol. 1996;156:3461-8.
179. Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L. Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol. 1995;155:2077-84.
180. Shearer JD, Richards JR, Mills CD, Caldwell MD. Differential regulation of macrophage arginine, metabolism, a proposed role in wound healing. Am J Physiol. 1997;272:E181-90.
181. Mills CD, Kincaid K, Alt JA, Heilman MJ, Hill AH. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol. 2000;164:6166-73.
182. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature (London). 1988;334:260-2.
183. Rutschman R, Lang R, Hesse M, Ihle JN, Wynn TA, Murray PJ. Cutting edge, Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol. 2001;166:2173-7.
184. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL- 10 and PGE2) in murine bone- marrow-derived macrophages. Biochem Biophys Res Commun. 1995;206:667-73.
185. Puddu P, Fantuzzi L, Borghi P, Varano B, Rainaldi G, Guillemard E, et al. IL-12 induces IFN- gamma expression and secretion in mouse peritoneal macrophages. J Immunol. 1997;159(7):3490-7.
186. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750-61.
187. Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. SciWorld Journ. 2011;11(2):391-402.
188. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253-68.
189. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon gamma upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med. 1998;187(12):2103-8.
190. Romo N, Magri G, Muntasell A, Heredia G, Baía D, Angulo A, et al. Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization. J Leuk Biol. 2011;90:717-26.
191. Pepper M, Jenkins MK. Origins of CD4(+) effector and central memory T cells. Nat Immunol. 2011;12:467-71.
192. Anthony RM, Urban Jr JF, Alem F, Hamed HA, Rozo CT, Boucher JL. Memory TH2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat Med. 2006;12:955-6.
193. Modolell M, Corraliza IM, Link F, Soler G, Eichmann K. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2. cytokines. Eur J Immunol. 1995;25:1,101.
194. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54-67.
195. Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-59.
196. Taetzsch T, Levesque S, McGraw C, Brookins S, Luqa R, Bonini MG, et al. Redox regulation of NF-κB p50 and M1 polarization in microglia. Glia. 2014. Epub: Oct 21.
197. Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A. 2009;106(35):14978-83.
198. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11):1618-29.
199. Ferguson LR, Karunasinghe N, Zhu S, Wang AH. Selenium and its' role in the maintenance of genomic stability. Mutat Res. 2012;733(1-2):100-10.
200. Shetty SP, Shah R, Copeland PR. Regulation of selenocysteine incorporation into the selenium transport protein, selenoprotein P. J Biol Chem. 2014;289(36):25317-26.
201. Ramanathan CS, Taylor EW. Computational genomic analysis of hemorrhagic fever viruses. Viral selenoproteins as a potential factor in pathogenesis. Biol Trace Elem Res. 1997;56(1):93-106.
202. Liang H, Zhou Z, Zhang S, Zen K, Chen X, Zhang C. Identification of Ebola virus microRNAs and their putative pathological function. Sci China Life Sci. 2014;57(10):973-81.
203. Sheng M, Zhong Y, Chen Y, Du J, Ju X, Zhao C, et al. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro. Sci China Life Sci. 2014;57(10):959-72.
204. Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, et al. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res. 2012;1:181-94.
205. Aarons GA, Wells RS, Zagursky K, Fettes DL, Palinkas LA. Implementing Evidence-Based Practice in Community Mental Health Agencies: A Multiple Stakeholder Analysis. Am J Public Health. 2009;99:2087-95.
206. de Almeida MJ, Carvalho Costa B, de Faria RM D, Figueiredo Soares T, Perlatto Moura E, Chiappelli F. Improving communication skill training in patient centered medical practice for enhancing rational use of laboratory tests: The core of bioinformation for leveraging stakeholder engagement in regulatory science. Bioinformation. 2013;9:718-20.
207. Moncrief JW. Telemedicine: the slow revolution. Adv Perit Dial. 2014;30:125-7.
208. Preston J, Brown FW, Hartley B. Using telemedicine to improve health care in distant areas. Hosp Community Psychiatry. 1992;43(1):25-32.
209. Bediang G, Perrin C, de Ruiz Castañeda R, Kamga Y, Sawadogo A, Bagayoko CO, et al. The RAFT Telemedicine Network: Lessons Learnt and Perspectives from a Decade of Educational and Clinical Services in Low- and Middle-Incomes Countries. Front Public Health. 2014;2:180.
210. Giles-Vernick T, Rupp S. People, great apes, disease, and global health in the northern forests of Equatorial Africa. In: Giles-Vernick T, Webb Jr LA, editors. Global health in Africa: Historical perspectives on disease control. Athens Ohio: Ohio University Press. 2013. p. 117-37.
211. Rupprecht CE, Hanlon CA, Slate D. Oral vaccination of wildlife against rabies: opportunities and challenges in prevention and control. Dev Biol. 2004;119:173-84.
212. Almeida MF, Martorelli LF, Aires CC, Barros RF, Massad E. Vaccinating the vampire bat Desmodus rotundus against rabies. Virus Res. 2008;137(2):275-7.
213. Anderson A, Shwiff S, Gebhardt K, Ramírez AJ, Shwiff S, Kohler D, et al. Economic evaluation of vampire bat (Desmodus rotundus) rabies prevention in Mexico. Transbound Emerg Dis. 2014;61(2):140-6.
214. Maganga GD, Bourgarel M, Vallo P, Dallo TD, Ngoagouni C, Drexler JF, et al. Bat distribution size or shape as determinant of viral richness in african bats. PLoS One. 2014;9(6):e100172. Epub June 24.